GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Construction In Progress

Nyrada (ASX:NYR) Construction In Progress : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Construction In Progress?

Nyrada Construction In Progress Historical Data

The historical data trend for Nyrada's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Construction In Progress Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Construction In Progress
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial - - - - -

Nyrada Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Nyrada (ASX:NYR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Construction In Progress
Comparable Companies
ASX:ANR ASX:HXL ASX:EX1 ASX:RGS ASX:NC6 ASX:ILA ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Website
https://www.nyrada.com
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines